眼底新生血管生物靶向抑制剂的相关研究进展  

Research Progress of Fundus Neovascularization Biotargeted Inhibitors

作　　者：李雪晨 LI Xuechen(Eye Institute and School of Optometry,Tianjin Medical University Eye Hospital,Tianjin Branch of National Clinical Research Center for Ocular Disease,Tianjin Key Laboratory of Retinal Functions and Diseases,Tianjin 300384,China)

机构地区：[1]天津医科大学眼科医院、眼视光学院、眼科研究所,国家眼耳鼻喉疾病临床医学研究中心天津市分中心,天津市视网膜功能与疾病重点实验室,天津300384

出　　处：《中国医药指南》2024年第10期59-62,共4页Guide of China Medicine

摘　　要：眼底新生血管可导致眼底病变,对视力造成不可挽回的伤害,影响正常生活。以往多用激光疗法,但其本身存在副作用,且难以扼制异常血管的再生。靶向抑制剂可通过免疫抑制或通路抑制在疾病中发挥根治作用,为明确其应用价值,现将大分子单克隆抗体、小分子酪氨酸激酶抑制剂和双特异性单克隆抗体的相关研究综述如下。Fundus neovascularization can cause fundus lesions,irreparable damage to vision,and affect normal life.Laser therapy has been used in the past,but it has side effects and is difficult to curb the regeneration of abnormal blood vessels.Targeted inhibitors can play a radical role in disease through immunosuppression or pathway inhibition.In order to clarify their application value,relevant studies on macromolecular monoclonal antibodies,small-molecule tyrosine kinase inhibitors and bispecial monoclonal antibodies are summarized below.

关 键 词：眼底新生血管 生物靶向抑制剂 雷珠单抗 阿柏西普 康柏西普 法瑞西单抗 

分 类 号：R988.1[医药卫生—药品]